Dietary Supplement Listing Act of 2026
To improve transparency and the availability of information regarding dietary supplements by amending the Federal Food, Drug, and Cosmetic Act to require manufacturers of dietary supplements to list dietary supplements with the Food and Drug Administration.
HB8370, also known as the Dietary Supplement Listing Act of 2026, aims to enhance transparency and the availability of information on dietary supplements. It proposes changes to the Federal Food, Drug, and Cosmetic Act, requiring manufacturers to list their dietary supplements with the Food and Drug Administration (FDA). This would help consumers and regulators better understand what's in the supplements they are using.
This bill would affect dietary supplement manufacturers, who would need to provide detailed information to the FDA about their products. Consumers would benefit from having clearer and more accessible information, which could help them make more informed choices about their health and wellness products. The FDA would also gain better oversight and management of the dietary supplement market.
HB8370 was introduced on April 20, 2026, and referred to the House Committee on Energy and Commerce the same day. It is currently in the initial stages of the legislative process, where it will be reviewed and possibly amended before moving forward.
